Reconciled ClinicalTrials.gov v2 Protocol Specification
| Protocol Field | Verified Registry Value |
|---|---|
| NCT Identifier | NCT05169567 |
| Consolidated Lead Sponsor | Eli Lilly and Company |
| Therapeutic Condition Cohort | Oncology and Hematology |
| Clinical Trial Phase | Phase III |
| Overall Recruitment Status | ACTIVE NOT RECRUITING |
| Registered Enrollment | 368 participants (ACTUAL) |
| Registered Start Date | 2022-03-11 |
| WhyStopped Classification | Not Stopped |
Named U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Site Profile |
|---|---|---|
| Providence Medical Foundation | Fullerton, CA | Open Hospital Dossier -> |
| Cancer and Blood Specialty Clinic | Los Alamitos, CA | Open Hospital Dossier -> |
| USC Norris Comprehensive Cancer Center and Keck Medicine | Los Angeles, CA | Open Hospital Dossier -> |
| UCLA Health and Jonsson Comprehensive Cancer Center | Los Angeles, CA | Open Hospital Dossier -> |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Eli Lilly and Company across sibling Meru public-data platforms.
Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.